OPEN END-TURBO-OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Real-time BOERSE MUENCHEN 07:36:04 2024-06-20 EDT | ||
| 25.44 EUR | -0.04% |
|
| Current month | +6.09% | ||
| 1 month | +9.60% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-20 | 25.44 | -0.04% |
| 24-06-19 | 25.45 | -0.12% |
| 24-06-18 | 25.48 | -2.52% |
| 24-06-17 | 26.14 | -2.64% |
| 24-06-14 | 26.85 | +1.51% |
Real-time BOERSE MUENCHEN
Last update June 20, 2024 at 07:36 am
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | HSBC |
| WKN | TR0VG9 |
| ISIN | DE000TR0VG97 |
| Date issued | 2017-10-06 |
| Strike | 195.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.9 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 27 € |
|---|---|
| Lowest since issue | 0.66 € |
| Spread | 0.16 € |
| Spread % | 0.63% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
467.3
USD
Average target price
463.4
USD
Spread / Average Target
-0.83%
- Stock Market
- Certificates
- Certificat
